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The role of endoscopy after upper gastrointestinal 





Upper gastrointestinal (UGI) bleed is a common surgical disease in sub-Saharan Africa where there is often a lack of  diagnostic and 
interventional adjuncts such as endoscopy. This study sought to characterize the role of  endoscopy in management of  acute UGI 
bleeding.
Materials and Methods
This is a prospective observational analysis of  adults presenting with an UGI bleed to a tertiary center in Lilongwe, Malawi, over two 
years. Patients were classified as having no endoscopy, diagnostic endoscopy, or endoscopy with variceal banding. Bivariate, survival 
analysis, and logistic regression analyses were used to compare intervention cohorts.
Results
293 patients were included with 49 patients (16.7%) receiving endoscopy with banding, 65 (22.2%) patients receiving diagnostic 
endoscopy only, and 179 (61.1%) receiving no endoscopy. Upon survival analysis comparing to the no endoscopy group, cox hazard 
modelling showed an adjusted hazard ratio over 30 days of  0.12 (95% CI 0.02, 0.88, p=0.038) for the endoscopic banding group and 
a hazard ratio of  0.39 (95% CI 0.13, 1.16, p=0.090) for the diagnostic endoscopy only group. Physical exam findings consistent with 
cirrhosis and decreasing age were independent predictors of  an endoscopic diagnosis of  variceal bleeding.
Conclusion
Esophagogastric varices are a common cause of  UGI bleeding in sub-Saharan Africa and can be predicted with age and physical exam 
findings. Endoscopy with variceal banding has a survival benefit for patients presenting with acute UGI bleed even with relatively 
low utilization. Appropriately triaging patients with likely variceal bleeding and improving endoscopy capacity would likely have a 
significant impact on mortality.
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Introduction
The burden of  surgical disease in sub-Saharan African 
currently exceeds the capacity for surgical care delivery.1 This 
is especially evident when multidisciplinary coordination 
and complex health system utilization is required, as with 
acute upper gastrointestinal (UGI) bleeding. A patient 
with acute UGI bleeding requires monitored resuscitation, 
timely transfusion services, endoscopic diagnostic and 
therapeutic adjuncts with available expertise, appropriate 
pharmacotherapy, and possibly surgical intervention.2,3
In sub-Saharan Africa, the etiopathogenesis of  UGI bleeding 
is heterogeneous with significant regional variation.4-11 In 
contrast to the United States and other high-income countries, 
esophagogastric varices (not peptic ulcer disease) are the 
predominant cause of  UGI bleeding in many regions.6-11 
Esophagogastric varices are often caused by liver cirrhosis, 
which has increased in incidence in this region. The burden 
of  liver cirrhosis rose by 57% over the last two decades and 
liver cirrhosis-related mortality doubled from 1980 through 
2010 throughout sub-Saharan Africa.12 This is attributable to 
the high prevalence of  Hepatitis B and C, alcohol use, and 
other regional pathologies such as schistosomiasis, which 
is endemic in Malawi.12,13 The data that the burden of  liver 
cirrhosis is increasing substantially in sub-Saharan Africa 
combined with evidence that esophagogastric bleeding is 
also increasing in incidence indicates this is an important 
public health issue.6
Our experience at a tertiary center in Malawi suggests 
an increase over time in the number of  patients with 
esophagogastric variceal bleeding but there is a dearth of  
data on the clinical characteristics and outcomes in this 
patient population in sub-Saharan Africa. Similarly, resource 
constraints further impact the utility of  diagnostic adjuncts 
and clinical management. When diagnostic and therapeutic 
interventions are scarce, providers must endeavour to 
appropriately triage patients who are most likely to benefit 
from any available therapeutic intervention. In this study, 
we sought to describe the role of  endoscopy in patients 
with acute UGI bleeding presenting to our center in Malawi 
and identify patient cohorts who would benefit most from 
diagnostic and therapeutic intervention. 
Methods 
This was a prospective observational study of  adult patients 
presenting to Kamuzu Central Hospital (KCH) with UGI 
bleeding from October 2011 to October 2013. KCH is a 
public 600-bed tertiary care hospital in the capital city of  
Lilongwe, which serves as a referral center for approximately 
5 million people in the central region of  Malawi. KCH is 
equipped with two esophagogastroduodenoscopes and two 
colonoscopes. 
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Patients were prospectively enrolled if  ≥ 18 years old, 
presented within 24 hours of  developing hematemesis or 
passage of  melanotic stools, and required hospital admission. 
Patients arriving at the hospital with UGI bleed in extremis 
were not enrolled. Baseline demographic and clinical data 
were obtained including presenting symptomatology, physical 
examination findings, vital signs, laboratory investigation 
results, and clinical outcome (lived/died). Post-discharge 
follow-up was obtained in clinic or via telephone. 
The primary outcome measure was mortality. 
The primary intervention for this analysis was 
esophagogastroduodenoscopy (EGD). Patients were 
categorized into three groups: (1) those that received 
no intervention, (2) diagnostic endoscopy only, and (3) 
diagnostic and therapeutic endoscopy (variceal banding). 
This is an observational study and all clinical interventions 
including the decision to schedule endoscopy and the use of  
variceal banding were made by the local clinicians based on 
clinical presentation and resource availability. KCH does not 
have the resources to perform emergent endoscopy. 
We initially examined the characteristics of  the sample 
population assessing the distribution of  the variables, and 
any impact of  missing data or extreme values. The mean, 
standard deviation, and the shape of  the distribution were 
calculated for each continuous variable, and frequencies 
were tabulated for categorical variables. To identify potential 
confounders, we examined the equality of  distribution of  
independent variables between the three groups, comparing 
means between groups for the continuous variables or 
percentages for the categorical variables. Bivariate analysis 
for each independent variable based on mortality outcome 
was performed using Pearson’s correlation for the categorical 
variables, and 2-sample t-tests or one-way analysis of  
variance for continuous variables. For continuous variables 
with non-parametric distributions, we used a Kruskal-Wallis 
test to compare medians. Means are reported with standard 
deviations (±). 
We used survival analysis to estimate the hazard ratio for in-
hospital mortality at thirty-days for both the diagnostic only 
group and the therapeutic endoscopy with variceal banding 
group compared to the reference group (no endoscopy 
group). Because there were no deaths in the therapeutic 
endoscopy group, we used an imputation strategy that 
allowed us to calculate a hazard ratio. A patient death was 
imputed in all three study groups with patient characteristics 
reflective of  the mean of  that respective study group. For 
categorical variables, each imputed patient was given the 
same characteristic variable value. We chose variable values 
that would give the most conservative model estimate of  
the adjusted hazard ratio. We initially plotted an unadjusted 
Kaplan-Meier curve comparing the three patient groups 
and then utilized a Cox regression model to estimate the 
mortality hazard ratio between the three patient groups, 
adjusting for confounders. Among potential confounders, 
we accessed and corrected for violation of  the proportional 
hazards assumption. A potential confounder was included 
in the model if  it substantially affected the adjusted hazard 
ratio. An adjusted hazard ratio and 95% confidence interval 
compared to the referent is reported for both intervention 
groups.
Finally, among the intervention arms, diagnostic only and 
diagnostic with therapeutic endoscopy, we used bivariate 
analysis to compare those with a positive endoscopic diagnosis 
of  variceal bleeding and those with another endoscopic 
diagnosis. Physical exam findings consistent with cirrhosis 
or portal hypertension were defined as the presence of  one 
or more of  the following: ascites, jaundice, hepatomegaly, or 
splenomegaly. Ultrasound findings consistent with cirrhosis 
or portal hypertension were defined as the presence of  one or 
more of  the following: ascites, hepatomegaly, splenomegaly, 
or cirrhotic liver. Multivariate logistic regression modelling 
was used to examine predictors of  endoscopically confirmed 
variceal bleeding. All clinically relevant variables were initially 
included. Variables were removed and reduced models were 
compared with a more complete, adjusted model using a 
maximum likelihood ratio test. If  there was no statistically 
significant difference between models, those variables 
were excluded in the final predictive model. Odds ratios 
and adjusted predicted probabilities with 95% confidence 
intervals are reported using the final model. 
All statistical analysis was performed using Stata/SE 13.1 
(Stata- Corp LP, College Station, TX).  The University of  
North Carolina Institutional Review Board (Study # 11-1649) 
and the Malawi National Health Services Review Committee 
(Protocol #891) approved this study, and consents were 
obtained from the patient or their relative if  they were not 
able to sign the consent. 
Results 
The study enrolled 293 patients with 179 patients (61.1%) 
in the control group, receiving no endoscopy. Among the 
remaining patients, 65 (22.2%) received diagnostic endoscopy 
only, and 49 patients (16.7%) received therapeutic endoscopy 
with banding. There was no statistically significant difference 
in the mean age between the three patient groups, with a 
mean of  41.6 ±16.1, 43.7 ±17.0, and 40.2 ±12.6 years for the 
control group, diagnostic endoscopy only and the therapeutic 
endoscopy, respectively (p=0.08) (Table 1). All three groups 
had a male preponderance (63.1%, 64.6%, 51.0%, p=0.051). 
Clinical history was statistically similar among all the three 
groups. There were more patients in the banding group with 
a previous history of  upper GI bleeding (35.8%, 32.3%, 
44.9%, p=0.62) but with fewer alcohol users (40.2%, 40.0%, 
26.5%, p=0.41) or smokers (27.9%, 26.2%, 14.3%, p=0.26). 
Nearly every patient presented with hematemesis (96.7%, 
96.9%, 95.9%, p=0.96) and a majority also had melena 
(64.8%, 69.2%, 71.4%, p=0.77).
Mean presenting heart rate was clinically similar among the 
three groups (100.0 ±19.6 bpm, 95.4 ±16.8 bpm, 97.7 ±25.0 
bpm, p=0.029) as was mean systolic blood pressure (106.7 
±18.6 mmHg, 108.7 ±21.8 mmHg, 103.3 ±18.5 mmHg, 
p=0.29). Patients who received either diagnostic endoscopy 
or endoscopy with banding were more likely to have their 
hemoglobin (48.6%, 70.8%, 77.5%, p<0.001) or platelet level 
(29.6%, 38.5%, 57.1%, p=0.002) measured at admission. 
Among those who had their hemoglobin measured at 
admission, there was a statistically significant difference in 
mean hemoglobin (g/dL) at 7.2 ±3.3, 8.1 ±4.1, and 6.2 ±2.2 
(p=0.001) for the three groups, respectively. Mean platelet 
count (x109/L) was lower in the banding group compared 
to the other two groups at 133.7 ±123.0, 253.0 ±214.6, and 
91.5 ±111.3 (p<0.001), respectively. 
Besides endoscopy, other common interventions used were 
blood product transfusions and pharmacotherapy including 
enteral propranolol after bleeding had stopped, omeprazole, 
spironolactone, and diuretics. In terms of  transfusion, 209 
(71.3%) patients were transfused with at least one unit of  












Mean (SD) 41.6 (16.1) 43.7 (17.0) 40.2 (12.6) 0.08
Sex: N (%)
Male 113 (63.1) 42 (64.6) 25 (51.0) 0.51
Clinical History 
Yes: N (%)
Had Previous Upper GI Bleed 64 (35.8) 21 (32.3) 22 (44.9) 0.62
Ever Drank Alcohol Regularly 72 (40.2) 26 (40.0) 13 (26.5) 0.41
Ever Smoked Tobacco Regularly 50 (27.9) 17 (26.2) 7 (14.3) 0.26
Vomiting Blood 173 (96.7) 63 (96.9) 47 (95.9) 0.96
Black Stools 116 (64.8) 45 (69.2) 35 (71.4) 0.77
Presenting Vital Signs: 
Mean (SD)
HR (bpm) 100.0 (19.6) 95.4 (16.8) 97.7 (25.0) 0.029




87 (48.6) 46 (70.8) 38 (77.5) <0.001
Hemoglobin (g/dL): 
Mean (SD)
7.2 (3.3) 8.1 (4.1) 6.2 (2.2) 0.001
Platelet Level Measured
Yes: N(%)
52 (29.6) 25 (38.5) 28 (57.1) 0.002
Platelets (x109/L): 
Mean (SD)
133.7 (123.0) 253.9 (214.6) 91.5 (111.3) <0.001
Received Other Interventions
Yes: N (%)
Packed Red Blood Cell Transfu-
sion
120 (67.0) 47 (72.3) 42 (85.7) 0.12
Fresh Frozen Plasma Transfusion 18 (10.1) 5 (7.7) 6 (12.2) 0.63
Platelet Transfusion 3 (1.7) 2 (3.1) 0 (0.0) 0.26
Propranolol 99 (55.3) 44 (67.7) 37 (75.5) 0.034
Proton Pump Inhibitor 34 (19.0) 21 (32.3) 14 (28.6) 0.063
Spironolactone 9 (5.0) 3 (4.6) 13 (26.5) <0.001
Diuretic 30 (16.8) 20 (30.8) 12 (24.5) 0.050
Transfusion: Number of Units
Mean (SD)
Packed Red Blood Cells 2.1 (1.4) 2.2 (1.4) 2.8 (1.4) 0.91
Time to Transfusion Initiation
Yes: N (%)
Admission Day 60 (50.0) 22 (46.8) 23 (54.8) 0.93
Day After Admission 27 (22.5) 10 (21.3) 9 (21.4)
Hospital Day 3 or Later 33 (27.5) 15 (31.9) 10 (23.8)
Time to Endoscopy (Days)
Mean (SD) n/a 11.8 (13.4) 11.7 (7.1) 0.99
Outpatient Follow-up
Yes: N(%)
Had Follow-up After Discharge 56 (31.3) 22 (33.9) 11 (22.5) 0.39
Table 1: Baseline characteristics of patients presenting with signs and symptoms of an upper gastrointestinal bleed 
stratified by whether they received no endoscopy, diagnostic endoscopy, or endoscopy with variceal banding
Malawi Medical Journal 32 (3); 139-145 September 2020 Endoscopy and upper GI bleeding in Africa  142
Https://dx.doi.org/10.4314/mmj.v32i3.6 
packed red blood cells (pRBC) or 
whole blood with only 29 (9.9%) 
patients receiving a plasma 
transfusion and 5 (1.7%) patients 
receiving a platelet transfusion. 
More patients in the banding 
group received a pRBC or whole 
blood transfusion compared to 
the other two groups (67.0, 72.3, 
85.7%, p=0.12) but each group 
had a similarly low proportion 
of  patients that received either 
fresh frozen plasma or a platelet 
transfusion. Among those who 
received a pRBC or whole blood 
transfusion, the number of  
transfused units was similar (2.1 
±1.4, 2.2 ±1.4, 2.8 ±1.4, p=0.91) 
despite significant differences 
in pre-transfusion hemoglobin 
levels. The timing of  transfusion 
was also similar in each of  the 
three groups with approximately 
half  of  patients in each group 
receiving their first transfusion 
on the day of  admission (50.0%, 
46.8%, 54.8%, p=0.93). A quarter of  patients received it on 
the day after admission (22.5%, 21.3%, 21.4%) and the rest 
either on hospital day three or later (27.5%, 31.9%, 23.8%). 
Propranolol was frequently used, especially in the endoscopy 
groups (55.2%, 67.7%, 75.5%, p=0.034) while omeprazole, 
spironolactone, and diuretics were used in less than 30% of  
patients.
We were able to follow-up post-discharge with relatively 
few patients in all three groups (Table 1; 31.3%, 33.9%, 
22.5%, p=0.39). Among those patients who had a follow-up, 
a higher proportion of  patients in the banding group had 
suffered a repeat UGI bleed (17.9%, 13.6%, 36.4%, p=0.27). 
Follow-up mortality was comparable but high for all three 
intervention groups (16.1%, 22.7%, 18.2%, p=0.79). 
Differences in mean time to endoscopy were not statistically 
significant in the two endoscopy groups, 11.8 ±13.4 days 
vs. 11.7 ±7.1 days, respectively (Table 1; p=0.99). Overall, 
only 11.1% of  patients received endoscopy within three days 
of  admission. Esophageal or gastric varices was the most 
common endoscopic diagnosis (64.0%), with indeterminate 
(14.9%) and gastric or duodenal ulcer (7.9%) as the second 
and third most common diagnosis, respectively (Figure 1). 
In-hospital crude mortality was significantly different 
between the three patient groups, 12.9%, 7.7%, and 
0.0%, respectively (p=0.021) (Table 1). A first episode of  
bleeding and receiving at least one pRBC or whole blood 
transfusion were both significantly associated with increased 
mortality. In addition, propranolol conferred a survival 
benefit with mortality rates of  6.7% and 14.2% in patients 
treated with and without propanol, respectively (p=0.034). 
Time to endoscopy, sex, alcohol use, presenting vital signs 
and laboratory studies, total units of  pRBCs, fresh frozen 
plasma transfusion, spironolactone administration, and 
proton pump inhibitor administration were not significantly 
associated with an increase in mortality on bivariate analysis.
Following imputation, an unadjusted Kaplan Meier survival 
analysis curve demonstrated a significant difference in the 
hazard of  30-day mortality among the three groups (Figure 
2, p=0.002). Cox hazard modeling showed a reduced hazard 
ratio of  0.12 (95% CI 0.02, 0.88, p=0.038) for the endoscopic 
banding group and a hazard ratio of  0.39 (95% CI 0.13, 1.16, 
p=0.090) for the diagnostic endoscopy group compared 
to the control group after adjusting for sex, propranolol 
administration, spironolactone administration, and whether 
the patient received a pRBC or whole blood transfusion. 
We also examined relationships between patient 
characteristics, clinical history, and exam findings with an 
endoscopic diagnosis of  variceal bleeding compared to those 
with a non-variceal endoscopic diagnosis. Mean age was 
significantly lower for those with a variceal diagnosis (39.6 
± 13.1 years vs. 46.8 ± 17.9 years, p=0.017) but sex was not 
table 1 cont....
Had Repeat UGI Bleed 10 (17.9) 3 (13.6) 4 (36.4) 0.27
Death after Discharge 9 (16.1) 5 (22.7) 2 (18.2) 0.79
Crude Mortality
N(%)
Died 23 (12.9) 5 (7.7) 0 (0.0) 0.021
Figure 1: Endoscopic diagnosis of  acute upper 
gastrointestinal bleeding for all patients who received 
endoscopy, with or without intervention
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different. There were more patients with a previous UGI 
bleed that had a variceal diagnosis (76.4% vs. 57.8%, p=0.039). 
Few patients had a platelet count among those who received 
endoscopy (n=53), but mean platelet count was significantly 
lower for those with a variceal diagnosis, 92.7 ±101.0 x 109/L 
vs. 359.1 ±213.8 x 109/L (p<0.001). Physical exam findings 
consistent with cirrhosis or portal hypertension (81.8% vs. 
41.7%, p<0.001) and ultrasound findings consistent with 
cirrhosis or portal hypertension (88.2% vs. 55.0%, p=0.001) 
both had significant associations with a variceal diagnosis. 
Upon multivariate logistic regression modeling, positive 
physical exam findings consistent with cirrhosis and younger 
age were both independent predictors of  an endoscopic 
diagnosis of  variceal bleeding. Ultrasound findings were not 
included in the model as they were only available in a small 
subset of  patients. Positive exam findings increased the odds 
of  an endoscopic variceal diagnosis (OR 7.69, 95% CI 3.10, 
19.12, p<0.001) while each ten-year increase in age decreased 
the odds of  an endoscopic variceal diagnosis (OR 0.68, 95% 
CI 0.51, 0.91, p=0.010). The predicted probability of  varices 
varied widely depending on age and physical exam findings 
(Table 2).
For basic patient characteristics and clinical history, no 
variable was missing in more than 2% of  patients. Vital 
signs were not documented in 8.9% of  patients and physical 
exam findings were not documented for 22.9% of  patients. 
We performed sensitivity analysis to assess any associations 
with missing vital sign or physical exam data by comparing 
patients with and without data.
There were no differences in patient characteristics, the 
intervention used, or mortality between patients with and 
without these data except that patients without documented 
clinical examination findings were less likely to receive 
endoscopy (23.1% vs. 8.2%, p=0.034). The similarities 
between those with and without complete records suggest 
that these data were missing at random.
Discussion 
The use of  diagnostic or therapeutic endoscopy is critical to 
the management of  patients with UGI bleeding regardless 
of  setting. Limited endoscopy availability requires that 
providers in low-resource environments make informed 
patient triage decisions for intervention. At our center, like 
others throughout the region, it is not possible to offer every 
patient diagnostic or therapeutic endoscopy following UGI 
bleeding, despite the associated survival benefits. 
In this study, we show that among patients presenting with 
acute UGI bleeding, endoscopy with variceal banding is 
lifesaving. In fact, over the two-year study period, no patient 
enrolled in the study died in the hospital after receiving 
banding. This was despite substantial delays in endoscopic 
intervention and limited blood transfusion services and 
pharmacotherapy. When adjusting for other commonly 
used therapies such as propranolol, the hazard ratio over 
thirty days was significantly lower for the endoscopy with 
banding group compared to no endoscopy. However, after 
adjustment, diagnostic endoscopy alone was not significantly 
associated with a decrease in the hazard of  mortality 
compared to no endoscopy. While diagnosis is imperative for 
directing therapy, banding is the only endoscopic intervention 
available at our center. If  patients did not receive banding, 
those in the diagnostic endoscopy group received the same 
pharmacotherapy as those who did not receive endoscopy. 
This similarity in medical therapy likely contributes to the 
similar hazard rates for the control group and the diagnostic 
endoscopy only group. 
Consistent with data from the region, our study also 
highlights the high prevalence of  variceal bleeding at our 
center with nearly two-thirds of  patients in the endoscopy 
cohort having that diagnosis.4,5,7-11 We posit that because 
patients with bleeding varices have a survival benefit after 
banding, patients with likely varices based on clinical markers 
should be prioritized for endoscopy. Previous meta-analyses 
have shown a survival benefit along with decreased rates of  
re-bleeding and complications with endoscopy compared to 
medical therapy as well as the superiority of  banding over 
sclerotherapy in most circumstances.14,15 Variceal bleeding 
is also less likely to stop spontaneously compared to non-
variceal bleeding. Less than 50% of  variceal bleeding stops 
spontaneously compared to 80% of  non-variceal bleeding.16,17
This study found that using age and physical exam findings 
together as predictors allows for simple triage of  patients 
who are more likely to benefit from therapeutic endoscopy. 
Younger patients (<40 years old) with physical exam findings 
consistent with cirrhosis had at least an 85% probability of  
varices in our model. While platelet count was not included 
in our model due to a small number of  patients having 
laboratory studies available, a lower platelet count was 
Table 2: Adjusted predicted probability of varices based on patient 









Physical Exam Findings 
Consistent with Cirrhosis 
or Portal Hypertension
Age (Years)
20 0.92 (0.81, 0.97) 0.61 (0.40, 0.78)
30 0.89 (0.78, 0.95) 0.51 (0.35, 0.67)
40 0.84 (0.73, 0.92) 0.41 (0.28, 0.56)
50 0.79 (0.66, 0.88) 0.33 (0.20, 0.49)
60 0.72 (0.54, 0.84) 0.25 (0.12, 0.43)
Figure 2: Kaplan-Meier Survival Estimates for 30-
Day In-Hospital Mortality stratified by whether they 
received no endoscopy, diagnostic endoscopy, or 
endoscopy with variceal banding, p=0.002
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significantly associated with varices and should likely be 
included in any triage algorithm if  available. A previously 
published prediction model for bleeding in patients with 
esophageal varices included anatomical characteristics of  
varices as well as liver function tests rarely available for most 
patients here and not currently practical in our environment.18
As demonstrated in this study, post-procedure follow-up in 
this region is generally poor which limits data collection on 
the long-term efficacy of  interventions. While there was no 
statistically significant mortality difference among the three 
groups, our data suggest there may be a higher proportion 
of  patients with re-bleeding among those with variceal 
bleeding with 36% reporting a repeat bleeding episode after 
discharge. This is consistent with studies in South Africa that 
have shown that repeat bleeding is common among patients 
with liver cirrhosis after banding.19-22 Post-discharge mortality 
was also very high at almost 20% for all three groups and 
may be attributable to the underlying disease pathology such 
as liver cirrhosis. This highlights that variceal banding is 
ultimately a temporizing measure that attenuates in-hospital 
mortality and should be considered as a bridge to definitive 
therapy such as portosystemic shunting. Though transjugular 
intrahepatic portosystemic shunts (TIPS) are not available in 
our resource-poor setting, portacaval and splenorenal shunts 
can be performed. 
In addition to appropriate triage for endoscopy, health care 
centers must work towards improving endoscopy capacity. 
Timely endoscopy was not available to all our patients who 
needed it due to staffing shortages of  both physicians and 
nurses. Banding materials were also difficult to obtain. Also, 
patients did not receive appropriate blood transfusions and 
appropriate pharmacotherapies like somatostatin analogues 
and vasopressin which remain unavailable. Large scale 
endoscopy improvement projects and training programs 
have been successfully implemented in sub-Saharan Africa 
and warrant further consideration for centers without robust 
endoscopy programs.23-25 
This study is limited by its observational methodology. 
Patients were not randomized to treatment thus exposing 
this study to possible selection bias. Overall, the three 
groups appear relatively similar and, with modeling, we 
attempted to control for potential confounders. However, 
in the cohort of  patients that did not receive endoscopy, the 
diagnosis of  esophagogastric varices is unknown. Therefore, 
the relative benefit of  endoscopy in that cohort cannot be 
quantified. Additionally, we have limited laboratory data that 
could otherwise be valuable for risk assessment of  patients. 
However, there are limited laboratory resources in our 
environment. Lastly, this study may be biased towards patients 
who survive a delay in treatment as many patients received 
endoscopic intervention several days after presentation. 
Conclusion
Esophagogastric varices are a common cause of  UGI 
bleeding in sub-Saharan Africa. In a resource-poor setting, 
its diagnosis can be predicted with age and physical exam 
findings. In addition, endoscopy with variceal banding has 
an in-hospital survival benefit for patients presenting with 
acute upper gastrointestinal bleeding even with relatively low 
utilization. Appropriately triaging patients with likely variceal 
bleeding and prioritizing the improvement of  endoscopy 
capacity would likely have a significant impact on mortality.
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